Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Eli Lilly and Company
Telix Pharmaceuticals (Innovations) Pty Limited
Hoffmann-La Roche
Stemline Therapeutics, Inc.
Hoffmann-La Roche
Neonc Technologies, Inc.
EMD Serono
Neonc Technologies, Inc.
Blueprint Medicines Corporation
Eli Lilly and Company
Incyte Corporation
Reveal Pharmaceuticals Inc.
Jazz Pharmaceuticals
ITM Solucin GmbH
Arbor Pharmaceuticals, Inc.
Massive Bio, Inc.
Pfizer
AbbVie
Varian, a Siemens Healthineers Company
RefleXion Medical
Plus Therapeutics
Binhui Biopharmaceutical Co., Ltd.
In8bio Inc.
Miltenyi Biomedicine GmbH
Regeneron Pharmaceuticals
BeiGene
Suzhou Maximum Bio-tech Co., Ltd.
Taproot Health
Daiichi Sankyo
EpicentRx, Inc.
Blaze Bioscience Inc.
EMD Serono
Celgene
Catalysis SL
Y-mAbs Therapeutics
Eisai Inc.
TVAX Biomedical
TVAX Biomedical
Helsinn Healthcare SA
Blaze Bioscience Inc.
Enzon Pharmaceuticals, Inc.
SynerGene Therapeutics, Inc.
Eli Lilly and Company
Bracco Diagnostics, Inc
Ono Pharmaceutical Co., Ltd.
Lisata Therapeutics, Inc.
Bracco Diagnostics, Inc
DNAtrix, Inc.